Study: 18F-Flotufolastat PET Imaging Changes Treatment in 89 Percent of Patients with Prostate Cancer Recurrence
For patients with recurrent prostate cancer, PET scanning with 18F-flotufolastat led to major changes in treatment for 80 percent of patients and 75 percent of patients with a changed treatment focus to watchful waiting had negative scans, according to new research presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU).
Emerging research from the SPOTLIGHT trial suggests the PET radiotracer 18F-flotufolastat may have a significant impact on treatment changes for patients with recurrent prostate cancer.
In a study, recently presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU) in San Francisco, researchers reviewed treatment plans prior to and after 97 patients with recurrent prostate cancer had positron emission tomography (PET) scans with 18F-flotufolastat (Posluma, Blue Earth Diagnostics).
The study authors noted this subgroup in comparison to the overall SPOTLIGHT study population had comparable percentages of prostatectomy procedures, Gleason scores and median prostate-specific antigen (PSA) levels.
The researchers found that 89 percent of the subgroup cohort (86 of 97 patients) had treatment changes after PET imaging and major changes to management plans occurred in 78 patients (80 percent). The study authors also noted negative 18F-flotufolastat PET scans for 75 percent of patients whose management plans were revised to watchful waiting.
In a new study, researchers found that 89 percent of patients with recurrent prostate cancer (86 of 97 patients) had treatment changes after PET imaging with 18F-flotufolastat and major changes to management plans occurred in 78 patients (80 percent). (Image courtesy of Blue Earth Diagnostics.)
“Both positive and negative 18F-flotufolastat PET scans did influence patient management. … We believe that treatment based on visualization of 18F-flotufolastat avid lesions may facilitate improved management of recurrent lesions,” noted study author Przemyslaw Twardowski, M.D., the director of clinical research in urology and urologic oncology at the Saint John’s Cancer Institute at Providence St. John’s Health Center in Santa Monica, Calif.
The study findings also revealed that 18F-flotufolastat PET scans revealed distant/extrapelvic lesions for all 15 patients whose treatment was changed from salvage therapy to non-curative systemic therapy.
“Treatment based on visualization of 18F-flotufolastat-avid lesions may facilitate optimal targeting of recurrence sites and avoid futile salvage therapy,” added Dr. Twardowski.
Reference
1. Twardowski P. Impact of 18F-flotufolastat PET on management of patients with recurrent prostate cancer: data from the SPOTLIGHT study. Poster presented at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU, San Francisco, Calif. Poster available at https://conferences.asco.org/gu/abstracts . Accessed January 25, 2024.
Meta-Analysis Shows No Difference Between bpMRI and mpMRI in Ruling Out csPCa
March 6th 2025In an 18-study meta-analysis involving over 4,600 patients, researchers found that bpMRI and mpMRI had equivalent pooled negative predictive value (NPV) of 92 percent for clinically significant prostate cancer (csPCa).
Can Deep Learning Ultra-Fast bpMRI Have an Impact in Prostate Cancer Imaging?
March 3rd 2025A deep learning-enhanced ultra-fast bpMRI protocol offered similar sensitivity for csPCa as mpMRI with an 80 percent reduction in scan time, according to research findings presented at the European Congress of Radiology (ECR) conference.
ECR Mammography Study: Pre-Op CEM Detects 34 Percent More Multifocal Masses than Mammography
February 28th 2025In addition to contrast-enhanced mammography (CEM) demonstrating over a 90 percent detection rate for multifocal masses, researchers found that no significant difference between histological measurements and CEM, according to study findings presented at the European Congress of Radiology.
Emerging AI Software for Prostate MRI Offers 95 Percent Sensitivity for csPCa
February 28th 2025In a multicenter study involving over 1,000 patients, a deep learning software offered comparable sensitivity and specificity for Gleason grade group > 2 tumors in comparison to radiologist interpretation.
